• LAST PRICE
    2.2300
  • TODAY'S CHANGE (%)
    Trending Up0.2500 (12.6263%)
  • Bid / Lots
    2.1800/ 82
  • Ask / Lots
    2.2400/ 45
  • Open / Previous Close
    2.0000 / 1.9800
  • Day Range
    Low 2.0000
    High 2.2400
  • 52 Week Range
    Low 1.2200
    High 5.8400
  • Volume
    55,925
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 1.98
TimeVolumeTH
09:59 ET7002
10:32 ET1002
10:44 ET25002
10:50 ET6002.03
11:08 ET1002.02
11:11 ET8002
11:15 ET10002
11:22 ET1002
11:24 ET10002
11:29 ET33002.05
11:31 ET7002.08
11:38 ET5002.08
11:45 ET1002.06
11:51 ET1002.06
11:58 ET1002.05
12:00 ET10002.06
12:09 ET40002.06
12:21 ET1002.05
12:25 ET3002.05
12:45 ET5002.01
01:21 ET6002.06
01:39 ET4002.07
01:42 ET63002.1
01:48 ET10002.1
02:09 ET10002.09
02:15 ET40002.1
02:20 ET1002.11
02:24 ET7002.1
02:51 ET7002.12
03:07 ET1002.12
03:16 ET1002.12
03:23 ET9002.14
03:32 ET10002.16
03:36 ET6002.18
03:38 ET66002.2
03:39 ET1002.22
03:41 ET41002.2
03:43 ET4002.19
03:50 ET69002.22
03:54 ET5002.24
03:57 ET11002.23
03:59 ET9002.23
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
CanadaTH
Theratechnologies Inc
90.9M
-1.7x
---
CanadaCOV
Covalon Technologies Ltd
28.8M
-6.0x
---
CanadaNUMI
Numinus Wellness Inc
30.1M
-1.0x
---
CanadaMBX
Microbix Biosystems Inc
51.5M
13.5x
---
CanadaMPH
Medicure Inc
12.5M
11.2x
-27.07%
CanadaARCH
Arch Biopartners Inc
138.1M
-71.8x
---
As of 2024-03-29

Company Information

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

Contact Information

Headquarters
2015 Peel Street, 11th FloorMONTREAL, QC, Canada H3A 1T8
Phone
514-336-7800
Fax
514-331-9691

Executives

Independent Chairman of the Board
Dawn Svoronos
President, Chief Executive Officer, Director
Paul Levesque
Chief Financial Officer, Senior Vice President
Philippe Dubuc
Senior Vice President, Chief Medical Officer
Christian Marsolais
Vice President - Finance
Marienoel Colussi

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$90.9M
Revenue (TTM)
$110.9M
Shares Outstanding
46.0M
Theratechnologies Inc does not pay a dividend.
Beta
1.72
EPS
$-1.30
Book Value
$-0.62
P/E Ratio
-1.7x
Price/Sales (TTM)
0.8
Price/Cash Flow (TTM)
---
Operating Margin
-17.18%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.